anti-CLL-1 CAR NK cells
Phase 1Cell therapy
anti-CLL-1 CAR NK cells is one of 13 small molecule programs targeting Relapsed/Refractory AML. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Relapsed/refractory AML
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Venclexta
AbbVieApproved
Leustatin
EMD SeronoApproved
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Luye
Ascentage Pharma Group Inc.Phase 2
Jakafi
IncytePhase 1
Lisaftoclax
Ascentage Pharma Group Inc.Phase 2
anti-CLL-1 CAR NK cells
SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory AML1 trial
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT06307054·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-CLL-1 CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details